68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer

European Urology

Volumn 70, Issue 4, 2016, Pages 553-557

  Herlemann, Annika ^a   Wenter, Vera ^b   Kretschmer, Alexander ^a   Thierfelder, Kolja M ^b   Bartenstein, Peter ^b   Faber, Claudius ^b   Gildehaus, Franz Josef ^b   Stief, Christian G ^a,b   Gratzke, Christian ^a,b   Fendler, Wolfgang P ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Lymph node dissection; PET CT; Positron emission tomography; Prostate cancer; PSMA

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; TRACER; UNCLASSIFIED DRUG; GALLIUM; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; AORTA; DIAGNOSTIC IMAGING; LYMPH NODE; PATHOLOGY; PELVIS; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; PROSTATE TUMOR; SACRUM; SURGERY;

ANTIGENS, SURFACE; AORTA; GALLIUM RADIOISOTOPES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; PELVIS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SACRUM;

EID: 84955266727     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.12.051     Document Type: Article

References (21)

1. [1] Heidenreich, A., Bastian, P.J., Bellmunt, J., et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65 (2014), 124–137.
2. [2] Briganti, A., Blute, M.L., Eastham, J.H., et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 55 (2009), 1251–1265.
3. [3] Cimitan, M., Bortolus, R., Morassut, S., et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33 (2006), 1387–1398.
4. [4] Heinisch, M., Dirisamer, A., Loidl, W., et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?. Mol Imaging Biol 8 (2006), 43–48.
5. [5] Vees, H., Buchegger, F., Albrecht, S., et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 99 (2007), 1415–1420.
6. [6] Husarik, D.B., Miralbell, R., Dubs, M., et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 35 (2008), 253–263.
7. [7] Krause, B.J., Souvatzoglou, M., Tuncel, M., et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35 (2008), 18–23.
8. [8] Afshar-Oromieh, A., Avtzi, E., Giesel, F.L., et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42 (2015), 197–209.
9. [9] Afshar-Oromieh, A., Malcher, A., Eder, M., et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40 (2013), 486–495.
10. [10] Eiber, M., Maurer, T., Souvatzoglou, M., et al. Evaluation of Hybrid (6)(8)Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 56 (2015), 668–674.
11. [11] Maurer, T., Weirich, G., Schottelius, M., et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol 68 (2015), 530–534.
12. 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 69 (2016), 393–396.
13. [13] Weineisen, M., Schottelius, M., Simecek, J., et al. 68Ga- and 177Lu-labeled PSMA I&T: Optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 56 (2015), 1169–1176.
14. [14] Taylor, A., Rockall, A.G., Powell, M.E., An atlas of the pelvic lymph node regions to aid radiotherapy target volume definition. Clin Oncol (R Coll Radiol) 19 (2007), 542–550.
15. [15] Harisinghani, M.G., Barentsz, J., Hahn, P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 (2003), 2491–2499.
16. [16] Tilki, D., Reich, O., Graser, A., et al. 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol 63 (2013), 792–796.
17. 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 2016;69:393–6. Eur Urol 70 (2016), e37–e38.
18. [18] Mattei, A., Fuechsel, F.G., Bhatta Dhar, N., et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 53 (2008), 118–125.
19. [19] Triantafyllou, M., Studer, U.E., Birkhauser, F.D., et al. Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur J Cancer 49 (2013), 616–624.
20. [20] Birkhauser, F.D., Studer, U.E., Froehlich, J.M., et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol 64 (2013), 953–960.
21. [21] Acar, C., Kleinjan, G.H., van den Berg, N.S., et al. Advances in sentinel node dissection in prostate cancer from a technical perspective. Int J Urol 22 (2015), 898–909.